Douglas Carr, who serves as Senior Vice President of Finance and Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), disposed of 1,654 shares of the company's common stock on June 12, 2026. The transaction totaled $3,691, with shares sold at a price of $2.232 each. The stock currently trades at $2.30, up nearly 300% over the past year and sitting about 24% below its 52-week high of $3.04.
The sale was not discretionary, as the shares were sold automatically to cover tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Mr. Carr directly holds 505,094 shares of Century Therapeutics common stock. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value, though the company maintains more cash than debt on its balance sheet.
In other recent news, Century Therapeutics presented preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the American Diabetes Association’s 86th Scientific Sessions. The therapy demonstrated sustained glucose control for over eight months in preclinical mouse models, utilizing the company’s Allo-Evasion 5.0 technology without the need for chronic immunosuppression. Additionally, Mizuho initiated coverage on Century Therapeutics with an Outperform rating, setting a price target of $8.00, highlighting the company’s advancements in cell therapy for Type 1 Diabetes. H.C. Wainwright also raised its price target for Century Therapeutics shares to $5.00 from $2.00, maintaining a Buy rating due to the potential of stem-cell-derived islet therapy for diabetes. Furthermore, Century Therapeutics updated its "at the market" equity offering program, with $131.6 million remaining available for future issuance and sale. The company has already sold shares worth approximately $18.4 million under this program. These developments underscore Century Therapeutics’ ongoing efforts in advancing diabetes treatment and securing financial resources for future initiatives.
Century Therapeutics
Follow
Analyze IPSC
Included in our AI-picked strategies
· Review strategies
2.30 ▲ +0.050 (+2.22%)
Closed · 15:59:59 · USD
2.30 0.000 (0.00%)
After Hours · 18:57:18
1D 1W 1M 6M 1Y 5Y Max
Analyze IPSC
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is IPSC a bargain right now?
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.
Get the bottom line for IPSC plus thousands of other stocks and find your next hidden gem with massive upside.
Flash Sale - Price Goes Up Soon
Century Therapeutics, Inc. (NASDAQ: IPSC) reported a recent insider transaction involving Senior Vice President of Finance and Operations Douglas Carr, who disposed of 1,654 shares on June 12, 2026. The sale, valued at $3,691, was executed at $2.232 per share and was not discretionary, serving to cover tax withholding obligations tied to the vesting of restricted stock units. Following this transaction, Carr retains a direct holding of 505,094 shares of the company's common stock. The stock currently trades at $2.30, reflecting a significant 300% gain over the past year, though it remains approximately 24% below its 52-week high of $3.04. According to InvestingPro analysis, the stock appears slightly overvalued relative to its Fair Value, yet the company maintains a balance sheet with more cash than debt. In broader corporate developments, Century Therapeutics has been actively advancing its pipeline and securing financial resources. The company presented preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the American Diabetes Association’s 86th Scientific Sessions. This therapy demonstrated sustained glucose control for over eight months in preclinical mouse models, utilizing Allo-Evasion 5.0 technology without the need for chronic immunosuppression. Analysts have responded positively to these advancements. Mizuho initiated coverage with an Outperform rating and an $8.00 price target, highlighting the company's progress in cell therapy for Type 1 Diabetes. H.C. Wainwright raised its price target to $5.00 from $2.00, maintaining a Buy rating due to the potential of stem-cell-derived islet therapy for diabetes. Additionally, Century Therapeutics updated its "at the market" equity offering program, with $131.6 million remaining available for future issuance and sale. The company has already sold shares worth approximately $18.4 million under this program. These activities underscore the company's efforts to advance diabetes treatment and secure financial resources for future initiatives.
Key Points
- Century Therapeutics presented preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the American Diabetes Association’s 86th Scientific Sessions, demonstrating sustained glucose control for over eight months in preclinical mouse models.
- Mizuho initiated coverage on Century Therapeutics with an Outperform rating and a price target of $8.00, while H.C. Wainwright raised its price target to $5.00 from $2.00, maintaining a Buy rating.
- Century Therapeutics updated its "at the market" equity offering program, with $131.6 million remaining available for future issuance and sale, and has already sold shares worth approximately $18.4 million under this program.
Risks
- The stock appears slightly overvalued relative to its Fair Value according to InvestingPro analysis, though the company maintains more cash than debt on its balance sheet.
- The company has already sold shares worth approximately $18.4 million under its "at the market" equity offering program, which may impact existing shareholders.
- The preclinical data presented for CNTY-813 is based on mouse models, and the long-term efficacy and safety in human patients remain to be determined.